Literature DB >> 28960185

Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?

Joseph Jankovic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28960185     DOI： 10.1038/nrneurol.2017.140

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Is Exenatide a Treatment for Parkinson's Disease?

Authors:  Dilan Athauda; Richard Wyse; Patrik Brundin; Thomas Foltynie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

2.  Insulin resistance and exendin-4 treatment for multiple system atrophy.

Authors:  Fares Bassil; Marie-Hélène Canron; Anne Vital; Erwan Bezard; Yazhou Li; Nigel H Greig; Seema Gulyani; Dimitrios Kapogiannis; Pierre-Olivier Fernagut; Wassilios G Meissner
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

3.  Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.

Authors:  Anamitra Ghosh; Trevor Tyson; Sonia George; Erin N Hildebrandt; Jennifer A Steiner; Zachary Madaj; Emily Schulz; Emily Machiela; William G McDonald; Martha L Escobar Galvis; Jeffrey H Kordower; Jeremy M Van Raamsdonk; Jerry R Colca; Patrik Brundin
Journal:  Sci Transl Med       Date:  2016-12-07       Impact factor: 17.956

4.  Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Dilan Athauda; Kate Maclagan; Simon S Skene; Martha Bajwa-Joseph; Dawn Letchford; Kashfia Chowdhury; Steve Hibbert; Natalia Budnik; Luca Zampedri; John Dickson; Yazhou Li; Iciar Aviles-Olmos; Thomas T Warner; Patricia Limousin; Andrew J Lees; Nigel H Greig; Susan Tebbs; Thomas Foltynie
Journal:  Lancet       Date:  2017-08-03       Impact factor: 79.321

5.  Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Authors: 
Journal:  Lancet Neurol       Date:  2015-06-23       Impact factor: 44.182

Review 6.  Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.

Authors:  Mark P Mattson
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

7.  Exenatide and the treatment of patients with Parkinson's disease.

Authors:  Iciar Aviles-Olmos; John Dickson; Zinovia Kefalopoulou; Atbin Djamshidian; Peter Ell; Therese Soderlund; Peter Whitton; Richard Wyse; Tom Isaacs; Andrew Lees; Patricia Limousin; Thomas Foltynie
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 8.  New and emerging medical therapies in Parkinson's disease.

Authors:  Mitesh Lotia; Joseph Jankovic
Journal:  Expert Opin Pharmacother       Date:  2016-02-19       Impact factor: 3.889

9.  Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.

Authors:  Lin Lu; Deng-Lei Fu; Hui-Qin Li; Ai-Ju Liu; Ji-Huang Li; Guo-Qing Zheng
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

Review 10.  Progress toward an integrated understanding of Parkinson's disease.

Authors:  Maxime W C Rousseaux; Joshua M Shulman; Joseph Jankovic
Journal:  F1000Res       Date:  2017-07-12
  10 in total
  5 in total

1.  Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease-Viewpoint.

Authors:  Carolina Sportelli; Daniele Urso; Peter Jenner; K Ray Chaudhuri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

2.  A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease.

Authors:  L Poupon-Bejuit; M P Hughes; W Liu; A Geard; N Faour-Slika; S Whaler; G Massaro; A A Rahim
Journal:  Sci Rep       Date:  2022-08-15       Impact factor: 4.996

Review 3.  Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.

Authors:  Bibhuti Bhusan Kakoti; Rajashri Bezbaruah; Nasima Ahmed
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

Review 4.  Old Drugs as New Treatments for Neurodegenerative Diseases.

Authors:  Fernando Durães; Madalena Pinto; Emília Sousa
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-11

5.  Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Authors:  Shuchun Chen; Seong-Jin Yu; Yazhou Li; Daniela Lecca; Elliot Glotfelty; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Nigel H Greig; Dong Seok Kim; Yun Wang
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.